BrightSpring Health Services (NASDAQ:BTSG) Releases Earnings Results, Beats Expectations By $0.07 EPS

Key Points

• BrightSpring beat third-quarter expectations: Adjusted EPS was $0.54 versus the $0.47 consensus, while revenue reached $4.21 billion compared with estimates of $3.88 billion. Revenue rose 26.4% year over year, supported by growth in Pharmacy Solutions and Provider Services.
• Management raised or reaffirmed an optimistic outlook: The company projects 2026 adjusted EBITDA of $850 million to $860 million and more than $700 million in operating cash flow, with leverage declining to 1.79 times.
• Pharmacy risks remain: Home and community pharmacy revenue fell 6% because of a roughly $50 million quarterly impact from the Inflation Reduction Act and exits from unprofitable customers. Shares nevertheless rose 9.2% following the results.

BrightSpring Health Services (NASDAQ:BTSG - Get Free Report) issued its quarterly earnings data on Friday. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.07, FiscalAI reports. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $3.88 billion. BrightSpring Health Services had a return on equity of 16.73% and a net margin of 2.55%. BrightSpring Health Services's quarterly revenue was up 26.4% on a year-over-year basis.

Here are the key takeaways from BrightSpring Health Services' conference call:

• Strong third-quarter performance: Revenue rose 26% year over year to $4.2 billion, adjusted EBITDA increased 42% to $228 million, and adjusted EPS grew 80% to $0.54. Results exceeded the company’s forecast, supported by broad-based growth across Pharmacy Solutions and Provider Services.
• Specialty and infusion pharmacy revenue grew 34%, driven by 29% script growth, strong branded limited-distribution drug launches, generic contributions, pharma services, and mid-teens growth in acute and chronic infusion. BrightSpring launched seven additional LDDs during the quarter and now supports 162 total therapies.
• Provider Services revenue increased 31%, with home health census up approximately 58% and continued momentum in rehab and personal care. Management expects the acquired Amedisys and LHC branches to contribute approximately $35 million of adjusted EBITDA in 2026.
• BrightSpring raised or reaffirmed a strong outlook, projecting 2026 adjusted EBITDA of $850 million-$860 million and more than $700 million of operating cash flow, while reiterating expectations for at least 15%-20% organic adjusted EBITDA growth in 2027. Leverage declined to 1.79 times, including the impact of $120 million in year-to-date share repurchases.
• Home and community pharmacy revenue declined 6% year over year, primarily because of approximately $50 million of quarterly impact from the Inflation Reduction Act and exits from uneconomic customers. Management expects the IRA to remain a roughly $50 million headwind in the fourth quarter, although underlying growth and profitability are improving.

BrightSpring Health Services Trading Up 9.2%

Shares of BTSG stock traded up $5.54 during trading hours on Friday, reaching $65.76. 3,848,451 shares of the stock were exchanged, compared to its average volume of 2,844,723. The firm has a market capitalization of $13.01 billion, a price-to-earnings ratio of 39.62, a price-to-earnings-growth ratio of 0.77 and a beta of 1.87. BrightSpring Health Services has a 12-month low of $30.64 and a 12-month high of $73.75. The company's 50-day moving average price is $59.79 and its 200-day moving average price is $54.40. The company has a current ratio of 1.59, a quick ratio of 1.22 and a debt-to-equity ratio of 1.06.

Key Headlines Impacting BrightSpring Health Services

Here are the key news stories impacting BrightSpring Health Services this week:

• Positive Sentiment: Quarterly earnings and revenue beat estimates. BrightSpring reported adjusted earnings of $0.54 per share, above consensus estimates ranging from $0.47 to $0.49 and up from $0.30 a year earlier. Revenue reached $4.21 billion versus the $3.88 billion consensus estimate. BrightSpring Q3 earnings and revenue results
• Positive Sentiment: Revenue growth remained strong. Sales increased 26.4% year over year, supporting the view that demand for BrightSpring’s home- and community-based healthcare services remains robust. BrightSpring Q3 revenue growth
• Positive Sentiment: Management raised full-year 2026 revenue and adjusted EBITDA guidance. The upgraded outlook is a significant bullish catalyst because it indicates that leadership expects the operating momentum to continue beyond the reported quarter. BrightSpring Q3 financial results and increased guidance
• Positive Sentiment: Profitability improved. The quarterly bottom line rose year over year, while reported net margin was 2.55% and return on equity was 16.73%, adding support to the positive earnings reaction. BrightSpring bottom-line growth
• Neutral Sentiment: The strong report follows a period in which investors questioned whether BrightSpring’s growth could offset ongoing risks tied to the Inflation Reduction Act and related healthcare reimbursement policies. Those issues remain important for future margins and guidance execution. BrightSpring earnings preview and IRA risks

Analyst Ratings Changes

Several analysts recently weighed in on BTSG shares. Wells Fargo & Company upped their price target on BrightSpring Health Services from $61.00 to $78.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $70.00 price target on shares of BrightSpring Health Services in a research report on Monday, August 3rd. Raymond James Financial started coverage on BrightSpring Health Services in a research report on Thursday, July 9th. They issued an "outperform" rating and a $80.00 price objective on the stock. Morgan Stanley upped their price target on BrightSpring Health Services from $71.00 to $80.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings cut BrightSpring Health Services from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, BrightSpring Health Services currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.88.

About BrightSpring Health Services

BrightSpring Health Services NASDAQ: BTSG is a Louisville, Kentucky-based provider of home- and community-based health services and pharmacy services. The company focuses on supporting individuals with complex or chronic care needs, including older adults and people with disabilities, through care delivered in homes, communities and other non-hospital settings.

Its services include home health, hospice, personal care, behavioral health, primary care, rehabilitation and community living programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.